Read More

DMK Pharmaceuticals Announces Presentation Of Preclinical Results Comparing Effects Of DPI-125 On Opioid Withdrawal Behaviors Versus Standard Of Care For Opioid Use Disorder At SfN Neuroscience 2023

DMK Pharmaceuticals Corporation (NASDAQ:DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today

DMK